JP2023536651A5 - - Google Patents
Info
- Publication number
- JP2023536651A5 JP2023536651A5 JP2023507861A JP2023507861A JP2023536651A5 JP 2023536651 A5 JP2023536651 A5 JP 2023536651A5 JP 2023507861 A JP2023507861 A JP 2023507861A JP 2023507861 A JP2023507861 A JP 2023507861A JP 2023536651 A5 JP2023536651 A5 JP 2023536651A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- il27rα
- sdab
- binding protein
- il27r
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025064081A JP7829773B2 (ja) | 2020-08-05 | 2025-04-09 | Ｉｌ２７受容体結合に関連する組成物および方法 |
| JP2026032985A JP2026090564A (ja) | 2020-08-05 | 2026-03-03 | Ｉｌ２７受容体結合に関連する組成物および方法 |
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063061562P | 2020-08-05 | 2020-08-05 | |
| US63/061,562 | 2020-08-05 | ||
| US202063078745P | 2020-09-15 | 2020-09-15 | |
| US63/078,745 | 2020-09-15 | ||
| US202163135884P | 2021-01-11 | 2021-01-11 | |
| US63/135,884 | 2021-01-11 | ||
| PCT/US2021/044577 WO2022031871A1 (en) | 2020-08-05 | 2021-08-04 | Compositions and methods related to il27 receptor binding |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025064081A Division JP7829773B2 (ja) | 2020-08-05 | 2025-04-09 | Ｉｌ２７受容体結合に関連する組成物および方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023536651A JP2023536651A (ja) | 2023-08-28 |
| JP2023536651A5 true JP2023536651A5 (enExample) | 2024-08-02 |
| JP7665730B2 JP7665730B2 (ja) | 2025-04-21 |
Family
ID=92301997
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023507861A Active JP7665730B2 (ja) | 2020-08-05 | 2021-08-04 | Ｉｌ２７受容体結合に関連する組成物および方法 |
| JP2025064081A Active JP7829773B2 (ja) | 2020-08-05 | 2025-04-09 | Ｉｌ２７受容体結合に関連する組成物および方法 |
| JP2026032985A Pending JP2026090564A (ja) | 2020-08-05 | 2026-03-03 | Ｉｌ２７受容体結合に関連する組成物および方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025064081A Active JP7829773B2 (ja) | 2020-08-05 | 2025-04-09 | Ｉｌ２７受容体結合に関連する組成物および方法 |
| JP2026032985A Pending JP2026090564A (ja) | 2020-08-05 | 2026-03-03 | Ｉｌ２７受容体結合に関連する組成物および方法 |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US11873349B1 (enExample) |
| EP (1) | EP4192502A4 (enExample) |
| JP (3) | JP7665730B2 (enExample) |
| KR (2) | KR20250159059A (enExample) |
| CN (1) | CN116829585A (enExample) |
| AU (1) | AU2021322238A1 (enExample) |
| CA (1) | CA3190420A1 (enExample) |
| MX (1) | MX2023001415A (enExample) |
| WO (1) | WO2022031871A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7641912B2 (ja) | 2019-04-19 | 2025-03-07 | シナーキン・ファーマ・ベスローテン・フエンノートシャップ | Ｉｌ１３を含む融合タンパク質 |
| US12122839B2 (en) | 2020-08-05 | 2024-10-22 | Synthekine, Inc. | IFNGR binding synthetic cytokines and methods of use |
| EP4192502A4 (en) * | 2020-08-05 | 2024-10-09 | Synthekine, Inc. | Compositions and methods related to il27 receptor binding |
| MX2023001491A (es) | 2020-08-05 | 2023-03-08 | Synthekine Inc | Moleculas de union a gp130 y metodos de uso. |
| WO2022031890A1 (en) | 2020-08-05 | 2022-02-10 | Synthekine, Inc. | Ifngr2 binding molecules and methods of use |
| KR102846963B1 (ko) | 2020-08-05 | 2025-08-18 | 신테카인, 인크. | IL27Rα 결합 분자 및 사용 방법 |
| JP7743500B2 (ja) | 2020-08-05 | 2025-09-24 | シンセカイン インコーポレイテッド | Ｉｌ１０受容体結合性分子および使用方法 |
| US20240052047A1 (en) * | 2022-08-03 | 2024-02-15 | Pfizer Inc. | Anti- il27r antibodies and methods of use thereof |
| CN120188293A (zh) | 2023-05-11 | 2025-06-20 | 株式会社Lg新能源 | 电池单体化成设备 |
| WO2025030130A1 (en) * | 2023-08-03 | 2025-02-06 | Chroma Medicine, Inc. | Methods and compositions comprising dnmt3a-binding antibodies |
| KR20260011639A (ko) * | 2024-07-16 | 2026-01-23 | 서울대학교산학협력단 | Il27 저해제를 이용한 sfts 바이러스 감염증 개선용 조성물 |
Family Cites Families (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| US8921528B2 (en) | 2004-06-01 | 2014-12-30 | Domantis Limited | Bispecific fusion antibodies with enhanced serum half-life |
| JP2008501706A (ja) | 2004-06-04 | 2008-01-24 | ジェネンテック・インコーポレーテッド | 疾患の治療方法 |
| EP1828250A2 (en) * | 2004-12-16 | 2007-09-05 | Genentech, Inc. | Methods for treating autoimmune disorders |
| US7612181B2 (en) | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
| DE602006009834D1 (de) | 2005-09-01 | 2009-11-26 | Schering Corp | Verwendung von il-23 und il-17-antagonisten zur behandlung von autoimmuner entzündlicher augenerkrankung |
| DK2046809T3 (en) * | 2006-07-19 | 2017-03-13 | Univ Pennsylvania | WSX-1 / IL-27 AS A TARGET OBJECTIVE FOR ANTI-INFLAMMATORY REACTIONS |
| CA2706425A1 (en) | 2007-11-27 | 2009-06-04 | Ablynx N.V. | Method for obtaining polypeptide constructs comprising two or more single domain antibodies |
| WO2010118243A2 (en) * | 2009-04-08 | 2010-10-14 | Genentech, Inc. | Use of il-27 antagonists to treat lupus |
| GB201005063D0 (en) | 2010-03-25 | 2010-05-12 | Ucb Pharma Sa | Biological products |
| UY33492A (es) | 2010-07-09 | 2012-01-31 | Abbott Lab | Inmunoglobulinas con dominio variable dual y usos de las mismas |
| CN105859889B (zh) * | 2010-11-17 | 2020-01-07 | 中外制药株式会社 | 具有代替凝血因子viii的功能的功能的多特异性抗原结合分子 |
| US20120201746A1 (en) | 2010-12-22 | 2012-08-09 | Abbott Laboratories | Half immunoglobulin binding proteins and uses thereof |
| WO2012097238A2 (en) | 2011-01-14 | 2012-07-19 | Five Prime Therapeutics, Inc. | Il-27 antagonists for treating inflammatory diseases |
| DK2714738T3 (en) | 2011-05-24 | 2019-01-28 | Zyngenia Inc | MULTIVALENT AND MONOVALENT MULTISPECIFIC COMPLEXES AND THEIR APPLICATIONS |
| EP2729488A4 (en) | 2011-07-06 | 2015-01-14 | Medimmune Llc | PROCESS FOR PREPARING MULTIMANT POLYPEPTIDES |
| US8790651B2 (en) | 2011-07-21 | 2014-07-29 | Zoetis Llc | Interleukin-31 monoclonal antibody |
| WO2013059299A1 (en) | 2011-10-17 | 2013-04-25 | The Uab Research Foundation | Antibodies for interferon subtypes and interferon/interferon receptor ternary complex and uses thereof |
| JP6693872B2 (ja) | 2013-07-25 | 2020-05-13 | シトムクス セラピューティクス，インコーポレイティド | 多重特異性抗体、多重特異性活性化可能抗体、及びそれらの使用方法 |
| US20160251440A1 (en) * | 2013-09-26 | 2016-09-01 | Ablynx N.V. | Bispecific nanobodies |
| CN122399016A (zh) | 2014-03-15 | 2026-07-17 | 诺华股份有限公司 | 使用嵌合抗原受体治疗癌症 |
| IL300029A (en) | 2014-05-16 | 2023-03-01 | Baylor Res Institute | Methods and preparations for the treatment of autoimmune and inflammatory conditions |
| AU2015366284B2 (en) | 2014-12-19 | 2021-07-22 | Ablynx N.V. | Cysteine linked nanobody dimers |
| HRP20191800T1 (hr) | 2015-05-13 | 2019-12-27 | Ablynx N.V. | Polipeptidi koji regrutiraju t stanice koji se temelje na tcr alfa/beta reaktivnosti |
| EP3297672B1 (en) | 2015-05-21 | 2021-09-01 | Harpoon Therapeutics, Inc. | Trispecific binding proteins and methods of use |
| PT3328894T (pt) | 2015-08-06 | 2019-02-13 | Agency Science Tech & Res | Anticorpos de cadeia comum gama/il2rbeta |
| CN107400166A (zh) | 2016-05-19 | 2017-11-28 | 苏州康宁杰瑞生物科技有限公司 | 针对ctla4的单域抗体及其衍生蛋白 |
| US12447213B2 (en) | 2016-10-07 | 2025-10-21 | The Broad Institute, Inc. | Modulation of novel immune checkpoint targets |
| CN110312736B (zh) | 2017-01-23 | 2023-05-09 | 苏州康宁杰瑞生物科技有限公司 | Pd-l1结合多肽或化合物 |
| EP3634465A4 (en) | 2017-05-25 | 2021-01-20 | The Broad Institute, Inc. | LYMPHOCYTE ANTIGEN CD5 SIMILAR (CD5L) MONOMER, HOMODIMER AND INTERLEUKIN 12B (P40) HETERODIMER ANTAGONISTS AND METHOD OF USE THEREOF |
| SG11202005146VA (en) * | 2017-12-18 | 2020-06-29 | Regeneron Pharma | Bispecific antigen binding molecules that bind leptin receptor and/or gp130, and methods of use thereof |
| SG11202004158QA (en) | 2017-12-28 | 2020-06-29 | Nanjing Legend Biotech Co Ltd | Single-domain antibodies and variants thereof against tigit |
| TW202010757A (zh) | 2018-04-11 | 2020-03-16 | 美商英伊布里克斯公司 | 具有經受限cd3結合的多重特異性多肽構築體以及相關方法及用途 |
| IL279367B2 (en) | 2018-06-13 | 2026-05-01 | Novartis Ag | BCMA chimeric antigen receptors and their uses |
| WO2019242632A1 (en) | 2018-06-19 | 2019-12-26 | 1§1Nanjing Legend Biotech Co., Ltd. | Engineered cells and uses thereof |
| AU2019321490B2 (en) | 2018-08-13 | 2025-09-04 | Inhibrx Biosciences, Inc. | Ox40-binding polypeptides and uses thereof |
| WO2020144164A1 (en) | 2019-01-07 | 2020-07-16 | Bactolife Aps | Pathogen binding proteins |
| GB201903767D0 (en) | 2019-03-19 | 2019-05-01 | Quadrucept Bio Ltd | Multimers, tetramers & octamers |
| CN111018985B (zh) | 2019-12-06 | 2021-06-18 | 南京融捷康生物科技有限公司 | 针对牛血清白蛋白bsa的单域抗体的应用 |
| KR20230061392A (ko) * | 2020-08-05 | 2023-05-08 | 신테카인, 인크. | 수용체 쌍형성과 관련된 조성물 및 방법 |
| EP4192502A4 (en) * | 2020-08-05 | 2024-10-09 | Synthekine, Inc. | Compositions and methods related to il27 receptor binding |
-
2021
- 2021-08-04 EP EP21853190.3A patent/EP4192502A4/en active Pending
- 2021-08-04 KR KR1020257035011A patent/KR20250159059A/ko active Pending
- 2021-08-04 KR KR1020237007563A patent/KR102875986B1/ko active Active
- 2021-08-04 JP JP2023507861A patent/JP7665730B2/ja active Active
- 2021-08-04 AU AU2021322238A patent/AU2021322238A1/en active Pending
- 2021-08-04 WO PCT/US2021/044577 patent/WO2022031871A1/en not_active Ceased
- 2021-08-04 CA CA3190420A patent/CA3190420A1/en active Pending
- 2021-08-04 CN CN202180068079.XA patent/CN116829585A/zh active Pending
- 2021-08-04 MX MX2023001415A patent/MX2023001415A/es unknown
-
2023
- 2023-02-03 US US18/164,386 patent/US11873349B1/en active Active
- 2023-09-11 US US18/464,998 patent/US12209132B2/en active Active
-
2025
- 2025-04-09 JP JP2025064081A patent/JP7829773B2/ja active Active
-
2026
- 2026-03-03 JP JP2026032985A patent/JP2026090564A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024522357A5 (enExample) | ||
| JP2022061992A5 (enExample) | ||
| JP2024167313A5 (enExample) | ||
| JP2009225799A5 (enExample) | ||
| JP2023527609A5 (enExample) | ||
| JP2021534762A5 (enExample) | ||
| JP2021191763A5 (enExample) | ||
| JP2023123726A5 (enExample) | ||
| JP2020511152A5 (enExample) | ||
| JP2020529830A5 (enExample) | ||
| JP2021530251A5 (enExample) | ||
| JP2023543493A5 (enExample) | ||
| JP2020508303A5 (enExample) | ||
| JP2019536430A5 (enExample) | ||
| JP2023540526A5 (enExample) | ||
| JP2019513370A5 (enExample) | ||
| JP2010535012A5 (enExample) | ||
| JP2022553129A5 (enExample) | ||
| WO2021063349A1 (zh) | 靶向bcma的抗体、双特异性抗体及其用途 | |
| US20110028695A1 (en) | Method for obtaining polypeptide constructs comprising two or more single domain antibodies | |
| JP2022547416A5 (enExample) | ||
| JP2015504306A5 (enExample) | ||
| JP2009517057A5 (enExample) | ||
| JP2011518886A5 (enExample) | ||
| JP2020535843A5 (enExample) |